The application of the Company’s technology is also anticipated to enable extension of patent life for existing therapeutics, thereby securing valuable intellectual property for longer term revenues. The Company has identified several candidate
drugs as being particularly suited to its needle-free delivery system (the “Particle Therapeutics Device”) and is considering adding a small number of these to its pipeline. The first of these, glucagon, has been selected on the basis of a very significant unmet clinical need which is ideally addressed by Particle Therapeutics’ innovative device and particle formulation technologies. There are compelling clinical, commercial and technical grounds for selecting glucagon, or needle-free delivery to patients experiencing severe hypoglycaemia, as the Company’s first product. Particle Therapeutics is developing single-use powder injection devices pre-filled with specially formulated powder particles.
The advantages of powder injection over conventional needle-and-syringe injection are as follows:
-No cross-contamination from needle or syringe re-use
-No particular skill is required to administer powder injections
-No perceived risk to the patient (e.g. injection of air, puncturing arteries)
-No bleeding, and the injection is virtually pain-free
-No “cold chain” of refrigeration, as with preservation of liquid drugs
The drug particles used for powder injection must be carefully formulated to ensure they have the chemical and physical properties to create the greatest therapeutic effect. The company has unique expertise in this area.
Visit the Official Company website.
No comments:
Post a Comment